Icu Medical Stock Price, News & Analysis

ICU Medical (Nasdaq:ICUI) announced its fourth quarter 2020 financial results, reporting revenues of $320.5 million, up from $315.5 million year-over-year. The GAAP gross profit rose to $119.9 million with a gross margin of 37%. Net income reached $26.1 million or $1.21 per diluted share, compared to $20.6 million or $0.96 per share in Q4 2019. Adjusted diluted EPS decreased to $1.77 from $1.94. For 2021, the company projects adjusted EBITDA between $245 million and $265 million, and adjusted diluted EPS of $6.50 to $7.20.

ICU Medical, Inc. (Nasdaq:ICUI) announced its participation at the Raymond James 42nd Annual Institutional Investors Conference, taking place virtually from March 1-3, 2021. The company’s management will deliver a presentation on March 1, 2021, at 1:40 p.m. PST (4:40 p.m. EST). Investors can access the live webcast on the company's website under the Investors tab and the Event Calendar tab, with a replay available afterward. ICU Medical specializes in innovative medical products for infusion therapy and critical care applications.

ICU Medical, Inc. (Nasdaq:ICUI) has announced the schedule for its fourth quarter and fiscal year 2020 earnings release and conference call. The earnings report will be released on February 25, 2021, at approximately 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET. Investors can access the call at (800) 936-9761 with conference ID 8029238 or via webcast on the company's website. ICU Medical specializes in innovative medical products for infusion therapy and critical care applications, helping to achieve clinical safety and workflow efficiency.

ICU Medical announced that its Plum 360 smart infusion system received the Best in KLAS honor as the top-performing Smart Pump EMR-Integrated. This recognition, a first by KLAS Research, highlights the Plum 360's alignment with industry guidelines for interoperable infusion systems. The award reflects feedback from thousands of healthcare professionals and emphasizes ICU Medical's leadership in infusion therapy. The company aims to enhance safety through improved integration with electronic medical records (EMR) and other systems, demonstrating a commitment to innovation and customer satisfaction.

ICU Medical (Nasdaq:ICUI) announced its participation in the J.P. Morgan 39th Annual Healthcare Conference, taking place virtually from January 11-14, 2021. The company's presentation is scheduled for January 13, 2021, at 8:40 a.m. PST (11:40 a.m. EST).

The event will be webcast live, accessible via the ICU Medical website under the Investors tab. The presentation will also be available for replay.

ICU Medical, Inc. (Nasdaq:ICUI) reported Q3 2020 revenues of $318.6 million, a $11.1 million increase year-over-year. However, GAAP gross profit declined to $113.9 million with a gross margin of 36%, down from 39% in Q3 2019. Net income was $25.0 million, or $1.16 per diluted share, down from $26.6 million or $1.24 per share in the same quarter last year. Adjusted EPS rose to $1.90 from $1.65. The company narrowed its 2020 adjusted EBITDA outlook to $235-$245 million and updated EPS guidance to $6.65-$7.00.

ICU Medical, Inc. (Nasdaq:ICUI) announced its third quarter 2020 earnings release on November 5, 2020, at 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET. The call can be accessed by dialing (800) 936-9761 with conference ID 9959519 and will also be available via webcast on the company's website. ICU Medical specializes in infusion therapy and critical care products, including IV smart pumps and other innovative medical solutions aimed at enhancing clinical safety and workflow.

ICU Medical, a leader in medical products for infusion therapy and critical care, announced its participation in the Morgan Stanley 18th Annual Global Healthcare Conference scheduled for September 14-18, 2020. The company will present virtually on September 17, 2020, at 12:30 PM Eastern Time. Interested parties can access the live webcast through the company's website under the Investors tab and the Event Calendar section. The presentation will also be available for replay.

ICU Medical reported second quarter 2020 revenues of $303.4 million, a decrease from $312.3 million in Q2 2019. The GAAP gross profit rose to $106.3 million, yielding a gross margin of 35%. Net income fell to $18.9 million or $0.88 per diluted share, down from $22.8 million or $1.06 per share a year prior. Adjusted diluted EPS decreased to $1.65 from $1.99. Demand for infusion pumps remained strong amid the COVID-19 pandemic.